Silence, AstraZeneca Ink siRNA Rx-Discovery Deal; Initial Focus on Respiratory Diseases

The deal with AstraZeneca, which is in line with Silence’s strategy of out-licensing its technology on a target-by-target basis, could be worth over $400 million to the RNAi drug developer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.